ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications.
It was founded in 2014 and is based in Boston, Massachusetts.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 12, 2018 | Series B | $14.40M | 2 | — | — | Detail |
Jun 27, 2017 | Series Unknown | $20M | 3 | — | — | Detail |
Dec 12, 2015 | Series A | $12.50M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
LabCorp | — | Series B |
MMIC Investment Holdings | — | Series B |
KTB-KORUS Fund | — | Series Unknown |
MGC Venture Partners | — | Series Unknown |
ORIG3N has acquired 1 organizations. Their most recent acquisition was Interleukin Genetics on Nov 22, 2017. They acquired Interleukin Genetics for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Nov 22, 2017
Interleukin Genetics
|
Biotechnology | acquisition | — | Detail |